Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 in eosinophilic asthma
CTR20222227Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic asthma (EA) comparing SHR-1703 with Placebo (2 arms). Primary endpoint: Change in blood eosinophil count from baseline. Started Sep 2022; status: completed.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20222227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222227.